Fibroblast growth factor-1

Summary

Fibroblast growth factor-1 (FGF-1), also known as acidic FGF (aFGF), is a pleiotropic signaling protein involved in angiogenesis, wound healing, neural development, and metabolic regulation. It is the broadest-spectrum FGF, binding all four FGFR subtypes. Recombinant and engineered forms are under investigation for cardiovascular disease, diabetic wound healing, and metabolic disorders. No forms are currently FDA-approved as standalone therapeutics, though clinical trials have been conducted.

Mechanism of Action

Binds to fibroblast growth factor receptors (FGFR1-4) and heparan sulfate proteoglycans, activating receptor tyrosine kinase signaling cascades (RAS/MAPK, PI3K/AKT, PLCγ) that promote cell proliferation, migration, differentiation, angiogenesis, and tissue repair.

Routes of Administration

Goals & Uses

• Neural tissue repair and neuroprotectionNeurologyLow
• Angiogenesis promotion in coronary artery diseaseCardiovascularModerate
• Diabetic wound healingDermatology/MetabolicModerate
• Peripheral arterial disease / critical limb ischemiaVascularModerate
• Metabolic syndrome / insulin sensitizationMetabolicLow

Contraindications

• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Proliferative RetinopathyOphthalmologyModerate
• History of solid organ malignancyOncologyHigh

Adverse Effects

• ProteinuriaRenalUncommon
• Injection site reactionsLocalCommon
• HypotensionCardiovascularUncommonLow blood pressure
• Fever / flu-like symptomsSystemicUncommon
• Theoretical Oncogenic RiskOncologyUnknown

Drug Interactions

• HeparinLow
• Anticoagulants (warfarin, DOACs)Moderate
• Bevacizumab (anti-VEGF agents)Moderate

Population Constraints

• Patients with diabetes mellitus (with retinopathy)ComorbidityRelative
• Pediatric patientsAgeRelative
• Immunocompromised patientsImmunologicRelative
• Patients with FGFR-mutant cancersOncology/GeneticAbsolute

Regulatory Status

• European UnionInvestigationalNo EMA-approved FGF-1 product; clinical trial applications have been filed in EU for gene therapy approaches.
• United StatesInvestigationalNV1FGF (Generx) and other FGF-1-based gene therapies have undergone FDA IND-permitted clinical trials but none have achieved FDA approval.
• United KingdomUnknownNo MHRA-approved FGF-1 product identified; treated as investigational.

No FDA, EMA, or MHRA-approved therapeutic product based solely on FGF-1 as of 2024. Various recombinant forms and gene therapy vectors encoding FGF-1 have entered clinical trials (e.g., NV1FGF/Generx for coronary artery disease). Trafermin (recombinant FGF-2) is sometimes confused with FGF-1; they are distinct. Classified as a research/investigational agent.

Evidence & Sources

No sources recorded yet.